Protalix BioTherapeutics (PLX) Non-Current Debt (2011 - 2017)
Protalix BioTherapeutics (PLX) posted quarterly Non-Current Debt of $4.3 million for Q3 2017, little changed year-over-year from $4.3 million in Q3 2016, and little changed quarter-over-quarter from $4.3 million in Q2 2017.
Protalix BioTherapeutics (PLX) Non-Current Debt (2011 - 2017) Analysis & Trends
Protalix BioTherapeutics' Non-Current Debt history runs 6 years deep, the most recent figure standing at $4.3 million for Q3 2017.
- In Q3 2017, Non-Current Debt changed 0.0% year-over-year to $4.3 million; the TTM figure through Sep 2017 stood at $4.3 million (changed 0.0% YoY), while the FY2016 annual figure was $4.3 million, changed 0.0% from the prior year.
- Non-Current Debt for Q3 2017 stood at $4.3 million, roughly flat from $4.3 million in the prior quarter.
- The five-year high for Non-Current Debt was $4.3 million in Q4 2015, with the low at $376000.0 in Q2 2013.
- The 4-year median for Non-Current Debt is $4.3 million (2015), against an average of $3.6 million.
- The sharpest annual moves came in 2013 and 2016: Non-Current Debt sank 91.97% in 2013, then changed 0.0% in 2016.
- Protalix BioTherapeutics' Non-Current Debt stood at $2.4 million in 2013, then surged by 81.4% to $4.3 million in 2015, then changed by 0.0% to $4.3 million in 2016, then changed by 0.0% to $4.3 million in 2017.
- Business Quant data shows PLX's Non-Current Debt at $4.3 million in Q3 2017, $4.3 million in Q2 2017, and $4.3 million in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 8.96 Bn |
| 10 | Protalix BioTherapeutics | 193.17 Mn | 152.51 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 4.30 Mn |
| Jun 30, 2017 | 4.30 Mn |
| Mar 31, 2017 | 4.30 Mn |
| Dec 31, 2016 | 4.30 Mn |
| Sep 30, 2016 | 4.30 Mn |
| Jun 30, 2016 | 4.30 Mn |
| Mar 31, 2016 | 4.30 Mn |
| Dec 31, 2015 | 4.30 Mn |
| Dec 31, 2013 | 2.37 Mn |
| Jun 30, 2013 | 376,000.00 |
| Mar 31, 2013 | 2.70 Mn |
| Dec 31, 2012 | 5.43 Mn |
| Sep 30, 2012 | 2.79 Mn |
| Jun 30, 2012 | 4.68 Mn |
| Dec 31, 2011 | 6.57 Mn |
| Sep 30, 2011 | 4.74 Mn |
| Jun 30, 2011 | 4.45 Mn |